We have been considering the optimum timing for the review of TA129 and TA171.  For TA129 and TA171, the manufacturers of bortezomib (Janssen) and lenalidomide (Celgene) each agreed a patient access scheme with the Department of Health.  Patient access schemes introduce complexity into the guidance review process.  As a consequence, we have decided to defer the consideration of the review of the guidance to allow for appropriate reflection on the existing patient access schemes. 

We will review this deferral decision in February 2012 and update you further at that time. 

November 2011